Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Otezla in active Behçet's disease
NCT02307513Phase 3Completed
- Sponsor
- Amgen
- Start
- Dec 2014
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of apremilast in Behçet's disease (BD), sponsored by Amgen. Started Dec 2014; status: completed.
02
Drugs
apremilast
03
Conditions
Behçet's disease (BD)
Beyond the preview
Go deeper on NCT02307513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02307513.